Mark Schoenberg - Jan 31, 2025 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Medical Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Jan 31, 2025
Transactions value $
-$50,698
Form type
4
Date filed
2/4/2025, 11:53 AM
Previous filing
Sep 12, 2024
Next filing
Jun 11, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +1.33K +0.92% 146K Jan 31, 2025 Direct F1
transaction URGN Ordinary Shares Sale -$8.46K -759 -0.52% $11.14 146K Jan 31, 2025 Direct F2
transaction URGN Ordinary Shares Options Exercise +3.33K +2.29% 149K Jan 31, 2025 Direct F1
transaction URGN Ordinary Shares Sale -$21.1K -1.9K -1.27% $11.14 147K Jan 31, 2025 Direct F2
transaction URGN Ordinary Shares Options Exercise +3.33K +2.27% 150K Jan 31, 2025 Direct F1
transaction URGN Ordinary Shares Sale -$21.1K -1.9K -1.26% $11.14 149K Jan 31, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -1.33K -100% $0.00 0 Jan 31, 2025 Ordinary Shares 1.33K Direct F1, F3
transaction URGN Restricted Stock Units Options Exercise $0 -3.33K -49.99% $0.00 3.33K Jan 31, 2025 Ordinary Shares 3.33K Direct F1, F4
transaction URGN Restricted Stock Units Options Exercise $0 -3.33K -33.33% $0.00 6.67K Jan 31, 2025 Ordinary Shares 3.33K Direct F1, F5
transaction URGN Restricted Stock Units Award $0 +20K $0.00 20K Jan 31, 2025 Ordinary Shares 20K Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3 The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023.
F4 The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024.
F5 The reporting person was granted RSUs on January 31, 2024 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025.
F6 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2026, January 31, 2027 and January 31, 2028.